Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is rare with a poor outcome and is resistant to conventional cytotoxic chemotherapy. The efficacy and safety of durvalumab and tremelimumab for treating recurrent or metastatic PSCs were assessed by a nonrandomized, open‐label, phase II study. METHOD...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Thorac Cancer
Glavni autori: Kim, Miso, Keam, Bhumsuk, Ock, Chan‐Young, Kim, Se Hyun, Kim, Yu Jung, Lim, Sun Min, Kim, Jin‐Soo, Kim, Tae Min, Hong, Sook‐Hee, Ahn, Mi Sun, Shin, Seong Hoon, Kang, Eun Joo, Kim, Dong‐Wan, Im, Sun‐Wha, Kim, Jong‐Il, Lee, Jong Seok, Kim, Joo‐Hang, Heo, Dae Seog
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2020
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7705626/
https://ncbi.nlm.nih.gov/pubmed/33026712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13684
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items